Is NCT06326411 recruiting in Tampa, FL?

Yes, NCT06326411 is currently recruiting participants at its Tampa, FL location. This oncology clinical trial is actively enrolling qualified participants.

How do I join the oncology clinical trial in Tampa?

To join this clinical trial in Tampa, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Tampa clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Oncology Clinical Trial in Tampa, FL

About This Oncology Study in Tampa

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

Sponsor: Nested Therapeutics, Inc

Who Can Participate

Inclusion Criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:

Subjects must be ≥18 years old (or of legal age of consent in the country in which the study is taking place) at the time of signing the informed consent.

Subjects who have a histologically or cytologically documented metastatic or locally advanced solid tumor, for which standard of care (SoC) therapy does not exist, no longer provides benefit, or is not tolerated by the subject, or the subject has been assessed by the Investigator as not being suitable for SoC therapy.

Part A: Subjects with any solid tumor with genetic alteration of or evidence of tumor dependence upon the RAS/MAPK pathway (subject to additional restrictions specified in the study protocol)

Part B: Subjects must be diagnosed with one of the following solid tumors harboring specified genetic alterations based on a validated local test: i. Melanoma Cohorts:

Activating NRAS mutations

Select BRAF alterations ii. Non-Melanoma Cohorts:

Solid tumors with NRAS activating mutations

Solid tumors with KRAS activating mutations

Solid tumors with select BRAF alterations

Glioma with BRAF alterations

Newly obtained or archived tumor tissue is required

Part B: measurable disease as defined by RECIST Version 1.1 or by other disease assessment tool standard for a given tumor type (if RECIST v. 1.1 is not standard)

Performance status

Solid tumors other than glioma: ECOG 0 or 1

Glioma: Karnofsky ≥ 70 and ECOG 0 or 1

Have adequate organ function

Understand and voluntarily sign an Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to any study-specific evaluation.

Life expectancy ≥ 12 weeks

Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

Conditions interfering with oral intake of NST-628

Conditions interfering with intestinal absorption of an orally administered drug

A history or current evidence of significant retinal pathology leading to increased risk of RVO

A history or evidence of cardiovascular risk

Current or history within 6 months of planned Cycle 1 Day 1 of pneumonitis or interstitial lung disease (ILD)

Part B: prior treatment with any MEK or BRAF inhibitor

Untreated or symptomatic central nervous system (CNS) metastases

Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1

Targeted small molecule agents within 14 days or 5 half-lives of Cycle 1 Day 1

Females who are pregnant or breastfeeding.

For fertile patients (female able to become pregnant or male able to father a child), refusal to use effective contraception during the period of the trial and for 6 months after the last dose of NST-628

Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT06326411) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Oncology Treatment Options in Tampa, FL

If you're searching for oncology treatment options in Tampa, FL, this clinical trial (NCT06326411) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this clinical trial. You'll receive care from experienced oncology specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all oncology clinical trials near you to find additional studies recruiting in your area.

Oncology Clinical Trial in Tampa, FL

Expert Care in Tampa

IRB Approved

No-Cost Care

Apply for This Tampa Location

Why Participate?

Simple Process